Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017

BOSTON, May 24, 2017 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at ASM Microbe 2017, to be held June 1 – 5 in New Orleans. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.